Day: February 26, 2021

SAN FRANCISCO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Kalytera Therapeutics, Inc. (TSX VENTURE EXCHANGE: KLY and OTC: KALTF) (the “Company” or “Kalytera“) today announced that its shares will resume trading today on the TSX VENTURE EXCHANGE (“TSXV”).The Company also announced that, pending TSXV approval, it will change its name to Claritas Pharmaceuticals, Inc.The Company is also pleased to announce the launch of its new website at http://www.claritaspharma.com/.The decision to rename the Company signals the re-launch of the Company, and its intent to focus on the development of its proprietary drug, R-107, for the treatment of vaccine-resistant strains of COVID-19 as well as other viral infections. R-107 is a nitric oxide releasing molecule designed to treat vaccine-resistant COVID-19 infection as well as the...

HAMILTON, Bermuda, Feb. 26, 2021 (GLOBE NEWSWIRE) — Enstar Group Limited (NASDAQ: ESGR) hat heute bekanntgegeben, dass eine ihrer hundertprozentigen Tochtergesellschaften eine Vereinbarung zur Bereitstellung von Adverse Development Cover (ADC) für AXA XL, einer Abteilung von AXA, unterzeichnet hat.Im Rahmen der Transaktion deckt die Tochtergesellschaft von Enstar Verluste vor und bis einschließlich 31. Dezember 2019 für einen diversifizierten Mix aus globalen Privat- und Berufshaftpflichtschäden. Die Prämie entspricht der Übertragung von Schadenrückstellungen in Höhe von 90 % von 1.550 Milliarden US-Dollar (respektive 1.395 Milliarden US-Dollar).Die Tochtergesellschaft von Enstar bietet 90 % Schutz (AXA XL übernimmt 10 %) auf zwei Ebenen. Die erste bietet eine Deckung von 1.550 Milliarden US-Dollar nach einem Selbstbehalt in Höhe...

TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Skylight Health Group Inc (TSXV:SHG; OTCQX: SHGFF) (“Skylight Health” or the “Company”), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce the appointment of Andrew Elinesky as Chief Financial Officer.Mr. Elinesky has a long and distinguished career in Finance and has served as CFO for multiple publicly traded companies in Canada and the United States. He comes with strong cross-border market experience and specializes in M&A and consolidation.Former SVP and CFO at McEwen Mining, a SEC registered multinational mining company listed on the NYSE and TSX with properties and operations in Canada, Argentina, Mexico, and the United Sates. Mr. Elinesky developed and implemented all aspects of company financial strategy, including respective...

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC), for patients two years of age and older.TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, eyes, kidneys and lungs, and in which epilepsy is the most common neurological feature. TSC is typically diagnosed in childhood.1“Epilepsy is reported...

LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines, today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the Company’s Type II variation application for EPIDYOLEX® (cannabidiol) as an adjunctive treatment of seizures associated with Tuberous Sclerosis Complex (TSC), for patients two years of age and older.TSC is a condition that causes mostly benign tumours to grow in vital organs of the body, including the brain, skin, heart, eyes, kidneys and lungs, and in which epilepsy is the most common neurological feature. TSC is typically diagnosed in childhood.1“Epilepsy is reported...

WOODBRIDGE, N.J., Feb. 26, 2021 (GLOBE NEWSWIRE) — NORTHFIELD BANCORP, INC. (NasdaqGS: NFBK), the holding company for Northfield Bank, collectively, the “Company,” announced that John W. Alexander, Chairman of Board, has advised the Company’s Boards of Directors that he will be retiring from the boards following the Annual Meeting of Stockholders on May 26, 2021. The Boards of the Company have selected Steven M. Klein, President & Chief Executive Officer to succeed Mr. Alexander as Chairman following his retirement.Annette Catino, Lead Independent Director, commented, “During Mr. Alexander’s over 20-year tenure as Chairman and Chief Executive Officer, and for more than three years as Chairman of the Board following his retirement as CEO, Northfield has had an enviable record of performance and has built significant value for...

CHMP has completed a review of available data for investigational antibody cocktail casirivimab and imdevimab (REGN-COV2) to be considered for the treatment of confirmed COVID-19  CHMP scientific opinion supports national decision making within EU states on the use of the antibodies before a formal authorisation is granted during a public health emergencyRoche and Regeneron are collaborating on developing and manufacturing casirivimab and imdevimab; Roche will be responsible for distribution in Europe and other countries outside the USBasel, 26 February 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) confirmed today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a scientific opinion supporting the use of the investigational antibody cocktail, casirivimab and imdevimab, as a...

February 26, 2021Dear Shareholders and Investors, Highlights: The following main elements in our business stand out at this time:During 2020 we distributed $67.2 million in cash dividends and repaid our existing loans with a gross amount of $75.5 million.The first half of 2020 was a strong period for NATThe third quarter of 2020 came out positively with a timecharter equivalent of about $25,000 per day per shipThe fourth quarter of 2020 was weakWe undertook planned technical maintenance of our ships during softer market periods of 2020 At the time of this report the market has improved and we believe that we are close to a significant positive turnaroundThe full year 2020 produced a net income of $50 million or an earning per share (EPS) of $0.34. This is an improvement of about $60 million in 2020 compared to 2019, which produced an...

On February 26, 2021 AB “Linas” Board confirmed AB “Linas” consolidated interim financial reports of twelve months of year 2020 which are not checked by the auditors and prepared acc.to International financial accountability standards accepted by EU.The sales incomes for January-December of year 2020 of AB “Linas” Group of companies made 14.01 mill. EUR. During the same period of year 2019 sales incomes were 12.98 mill. EUR.Profit before taxation of the twelve months of year 2020 of AB “Linas” group of companies – 0.62 mill. EUR. Group result for same period of year 2019 – 0.13 mill. EUR profit.Presenting confirmation of the responsible persons of AB “Linas” and interim consolidated not audited financial information of twelve months of year 2020.AB “Linas” chief of financeEgidijus Mikeliūnas+370 45 506100AttachmentTarpinė konsoliduota...

2021 m. vasario 26 d. AB „Linas“ valdyba patvirtino auditorių netikrintas AB „Linas“ 2020 metų dvylikos mėnesių konsoliduotas tarpines finansines ataskaitas, parengtas pagal ES priimtus Tarptautinius finansinės atskaitomybės standartus.AB „Linas“ Grupės 2020 metų sausio-gruodžio mėnesių pardavimo pajamos sudarė 14,01 mln. eurų, kai 2019 m. tuo pačiu laikotarpiu – 12,98 mln. eurų.AB „Linas“ įmonių grupės 2020 metų dvylikos mėnesių pelnas prieš apmokestinimą – 0,62 mln. eurų. 2019 m. to paties laikotarpio Grupės rezultatas – pelnas 0,13 mln. eurų.Pateikiame AB „Linas“ atsakingų asmenų patvirtinimą ir 2020 m. dvylikos  mėnesių tarpines konsoliduotas neaudituotas finansines ataskaitas.AB „Linas“ finansų vadovasEgidijus Mikeliūnas+370 45 506100PriedasTarpinė konsoliduota atskaitomybė už 2020 4ketv. LTU